March 17, 2020 / 7:16 AM / 21 days ago

AstraZeneca's combo lung cancer treatment fails late-stage study main goal

March 17 (Reuters) - AstraZeneca Plc said on Tuesday its combo treatment for a form of lung cancer failed to meet the main goal of improving overall survival in patients in a late stage study.

The study tested the combination of Imfinzi and tremelimumab as a first-line treatment in patients with extensive-stage small cell lung cancer, the company said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below